Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Dermatological Agent
100%
Adverse Event
58%
Epidermal Growth Factor Receptor Kinase Inhibitor
40%
Dermatology
30%
Exanthem
29%
Hidradenitis Suppurativa
23%
Diseases
22%
Systematic Review
21%
Nail
20%
Epidermal Growth Factor Receptor
19%
Skin Toxicity
19%
Erythema
18%
Corticosteroid
15%
Generalized Pustular Psoriasis
15%
Immune-Related Adverse Events
15%
Medical Dermatology
15%
Tumor Treating Fields
15%
EGFR Inhibitors
15%
Papulopustular
15%
Malignant Neoplasm
12%
Quality of Life
12%
Cancer Treatment
12%
Cancer Therapy
12%
Cytotoxic Chemotherapy
11%
Targeted Therapy
11%
Skin Manifestation
11%
Side Effect
11%
Treatment Option
11%
Skin Cancer
11%
Folliculitis
10%
Cytotoxic Agent
10%
Immunosuppressive Treatment
9%
Metastatic Colorectal Cancer
9%
Glioblastoma
9%
Acneiform Eruption
9%
Paronychia
9%
Retrospective Cohort Study
8%
T Cell
8%
Etiology
8%
Clinical Trial
8%
Placebo-Controlled Study
7%
Prevalence
7%
Chimeric Antigen Receptor T-Cell Immunotherapy
7%
Chimeric Antigen Receptor T-Cell
7%
COVID-19
7%
Onychomadesis
7%
Drug Intolerance
7%
Areola
7%
Hyperkeratosis
7%
Loeys-Dietz Syndrome
7%
Keyphrases
Spesolimab
56%
Generalized Pustular Psoriasis
48%
Dermatological Adverse Effects
32%
Hidradenitis Suppurativa
31%
Dermatological Diseases
23%
Epidermal Growth Factor Receptor Inhibitors (EGFRI)
23%
Psoriasis Flare
21%
Randomized Placebo-controlled Trial
15%
ASCO Guidelines
15%
National Health Interview Survey
15%
Psoriasis
15%
NHANES
15%
Plain Language Summary
15%
Safety Events
15%
Immune-related Adverse Events (IrAEs)
15%
Hematopoietic Stem Cell Transplant
15%
Dermatologic Toxicity
14%
Patients with Cancer
14%
Dermatologist
12%
Cancer Therapy
11%
Erythema
11%
Placebo
10%
Moderate to Severe
10%
Cancer Treatment
10%
Treatment Options
9%
Chronic Graft-versus-host Disease (cGVHD)
9%
Oncologists
9%
Physician Global Assessment
9%
Assessment Score
9%
Paronychia
9%
BRAF Inhibitor (BRAFi)
9%
Retrospective Cohort Study
9%
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis (SJS/TEN)
9%
Effisayil 1
8%
Life-threatening
8%
Corticosteroids
8%
Inhibitor Therapy
7%
United States
7%
Toxic Epidermal Necrolysis
7%
Stevens-Johnson Syndrome
7%
Skin Toxicity
7%
Cutaneous Manifestations
7%
Oncology
7%
Loeys-Dietz Syndrome
7%
Early Post-transplant Period
7%
Chimeric Antigen Receptor T Cells (CAR-T)
7%
Transplantation
7%
Matched Unrelated
7%
Onychomadesis
7%
Emergency Department Return
7%